SynthesisFrontiers in oncology2026
18F-FDG PET/CT for predicting major pathological response to neoadjuvant therapy in non-small cell lung cancer: a meta-analysis.
Synthesis in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To comprehensively evaluate the diagnostic utility of metabolic parameter changes on 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) for predicting pathological response after neoadjuvant therapy in patients with non-small cell lung cancer (NSCLC). Methods: The Cochrane Library, Web of Science, Embase, and PubMed were comprehensively retrieved up until October 2024 to identify diagnostic test accuracy studies evaluating the predictive efficacy of 18F-FDG PET/CT for postoperative pathological response in NSCLC patients following neoadjuvant therapy. Two independent reviewers screened studies, collected information, and evaluated the risk of bias. Statistical analysis was conducted via Meta-Disc 1.4 and Stata 17.0 software. Results: Fourteen eligible investigations encompassing 1,315 subjects were incorporated. The findings revealed that for predicting major pathological response (MPR) after neoadjuvant therapy, the metabolic parameter ΔSUVmax% on 18F-FDG PET/CT achieved an area under the summary receiver operating characteristic curve (sAUC) of 0.96 (95% CI: 0.94-0.97), with pooled sensitivity and specificity of 0.87 (0.73-0.94) and 0.93 (0.84-0.97), respectively. Similarly, the parameter SUVmax itself yielded an sAUC of 0.95 (0.93-0.96), with sensitivity of 0.80 (0.63-0.91) and specificity of 0.94 (0.87-0.97). Stratified analyses indicated that the neoadjuvant treatment regimen (single-modality vs. combination therapy), the cut-off value (<55% vs. ≥55%), sample size (<40 vs. ≥40), and the proportion of adenocarcinoma in the study sample (<40% vs. ≥40%) were potential sources of heterogeneity. Conclusion: Quantitative metabolic metrics derived from 18F-FDG PET/CT (ΔSUVmax% and SUVmax) demonstrate high diagnostic performance for pathological response after neoadjuvant therapy in NSCLC. These metrics may serve as noninvasive adjunct tools for response assessment, supporting individualized neoadjuvant strategies and facilitating clinical trial design in the perioperative immunotherapy era. However, given the limited number and quality of the available studies, these findings require confirmation through high-quality research. Systematic review registration: https://www.crd.york.ac.uk/prospero/, identifier CRD42024612056.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.